ALK-Abelló (ALK) Q4 2024 earnings summary

Executive summary

• Revenue grew 15% year-over-year to DKK 5,537 million, driven by strong European tablet sales and strategic execution.

• EBIT increased by 65% to DKK 1,091 million, with margin expansion and operational efficiencies.

• Strategic progress included expansion in respiratory allergy, anaphylaxis, and food allergy markets, and the launch of a new strategy.

• The ALK-Abelló Plus strategy delivered market expansion, new product launches, and cost optimization initiatives exceeding DKK 250 million in savings.

• 2024 saw significant progress in pediatric launches, regulatory approvals, and the in-licensing of Neffy, a nasal spray for anaphylaxis.

Financial highlights

• Q4 revenue up 11% to DKK 1.5 billion; full-year revenue up 15% to DKK 5,537 million.

• Gross profit reached DKK 3,552 million, with a gross margin of 64.2%, up from 62.9% year-over-year.

• EBIT was DKK 1,091 million, up 65%; EBIT margin rose from 14% to 20%.

• Free cash flow improved to DKK 292 million from negative DKK 204 million, impacted by a DKK 1 billion upfront payment for Neffy.

• Capacity costs increased by 4% to DKK 2.5 billion, including DKK 75 million in one-off optimization expenses.

Outlook and guidance

• 2025 revenue expected to grow 9%-13%, with EBIT margin projected at 20–25%.

• Double-digit tablet sales growth anticipated in all regions, though European growth will moderate due to reduced pricing/rebate effects.

• Neffy nasal spray expected to contribute to growth from H2 2025; gross margin to improve slightly but offset by Neffy-related costs.

• R&D expenses to remain around 10% of revenue, potentially rising to 12-13% in coming years.

• No one-off optimization costs assumed in 2025 guidance.